UCB posts more supportive data from Humira rival bimekizumab

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another set of supportive trial data in psoriasis.